Replimune Group, Inc. $REPL Shares Purchased by Readystate Asset Management LP

Readystate Asset Management LP lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 116.6% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 299,958 shares of the company’s stock after purchasing an additional 161,470 shares during the period. Readystate Asset Management LP’s holdings in Replimune Group were worth $3,321,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Replimune Group during the second quarter worth about $99,171,000. Balyasny Asset Management L.P. increased its stake in shares of Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after buying an additional 2,195,448 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Replimune Group in the fourth quarter valued at $17,568,000. Commodore Capital LP acquired a new stake in Replimune Group during the fourth quarter worth approximately $13,851,000. Finally, EcoR1 Capital LLC acquired a new stake in Replimune Group during the 1st quarter worth $7,650,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on REPL. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research note on Tuesday, June 30th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. Wolfe Research raised Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target for the company in a report on Friday, August 7th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the sale, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. This represents a 4.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the sale, the chief accounting officer directly owned 99,425 shares of the company’s stock, valued at approximately $1,289,542.25. This trade represents a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock worth $1,038,364 in the last 90 days. Company insiders own 5.40% of the company’s stock.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $15.04 on Monday. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $16.33. The company has a market capitalization of $1.41 billion, a PE ratio of -4.77 and a beta of 0.94. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The firm’s 50-day moving average is $12.25 and its two-hundred day moving average is $8.61.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Equities analysts anticipate that Replimune Group, Inc. will post -2.81 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.